|
The reported adverse event/incident was investigated in alignment with endologix operating procedures and work instructions.Where possible, it is endologix practice to make at least three good faith efforts to retrieve a reported adverse event/incident related device as well as medical records and medical imaging.An evaluation of the manufacturing record was completed.A review of the part number/lot number combination needed for device identification shows the device to have been properly manufactured and released in accordance with the device master record.The review confirms there were no manufacturing or processing non-conformities identified that would contribute to the reported adverse event/incident.An evaluation of the device could not be completed.The device was not returned to endologix for evaluation because it remains implanted.A clinical evaluation of the adverse event/incident was completed.An examination of medical records and/or medical imaging received by endologix shows the type 3b endoleak and re-intervention procedure are confirmed.The infection is unconfirmed due to a lack of the medical records.This is moderately consistent with the reported adverse event/incident.This was an off-label case due to concomitant use with products outside the ifu, however unable to confirm if this contributed to the reported event.Procedure related harms, device, user, procedure or anatomy relatedness of this complaint could not be determined with the medical records available for review.The final patient status was reported as the patient is now taking antibiotics for the treatment of the infection; however, the infection condition is not stable.No additional investigation of this reported adverse event/incident is planned.However, should additional information relevant to the investigation outcome become available, a follow-up report will be submitted.Endologix will continue to monitor this and similar adverse events/incidents.Device iteration is afx2.
|
|
The patient was initially implanted with an afx2 bifurcated stent graft, a vela suprarenal aortic extension and a gore excluder (non-endologix iliac limb) to treat an abdominal aortic aneurysm (aaa).This initial procedure is outside the indications of use (off-label) due to the use of adjunctive devices not compatible with afx system per the ifu.Approximately three and a half (3.5) years post initial procedure, the patient was found to have an unknown type of infection and open surgery was being was being discussed.Upon further follow-up a type 3b endoleak was suspected.On (b)(6) 2023 a secondary procedure was completed and the physician elected to reline the original implanted devices with another afx2 bifurcated stent graft and the type 3b endoleak was successfully resolved.The patient was placed on antibiotics for treatment of the infection; however, the infection condition is currently not stable and the physician stated there is a possibility of explanting the stent grafts at a later date if necessary.
|
